Literature DB >> 6277894

Structural characterization of neutral oligosaccharides of human midcycle cervical mucin.

E C Yurewicz, F Matsuura, K S Moghissi.   

Abstract

It was previously shown that alkaline borohydride treatment of human midcycle cervical mucin releases a heterogeneous population of reduced neutral, sialylated, and sulfated oligosaccharides (Yurewicz, E. C., and Moghissi, K. S. (1981) J. Biol. Chem. 256, 11895-11905). Three major neutral oligosaccharides were isolated with approximate compositions of Fuc:Gal:GlcNAc:N-acetylgalactosaminitol (GalNAcol) = 0:2:1:1 (A1), 1:2:1:1 (A2), and 2:2:1:1 (A3). They comprised roughly 21%, 13%, and 8% of human cervical mucin oligosaccharide chains, respectively. In the present report, each was analyzed by periodate oxidation, methylation, and sequential degradation with glycosidases. A1 was shown to contain more than one component, but structural analyses clearly demonstrated the presence of one predominant (75%) tetrasaccharide. The proposed structure, Gal beta 1-4GlcNAc beta 1-6(Gal beta 1-3)GalNAcol, has previously been found in human gastric, submaxillary, and ovarian cyst mucins in their carbohydrate-to-protein linkage regions. beta-Galactosidase from Aspergillus niger selectively cleaved the Gal beta 1-4GlcNAc linkage in the intact tetrasaccharide. Enzymatic hydrolysis of the Gal beta 1-3GalNAcol linkage required prior removal of the Gal beta 1-4GlcNAc beta 1-unit attached to 0-6 of GalNAcol. The data for A2 indicated a mixture of two oligosaccharides, Gal beta 1-4,3(Fuc alpha 1-3,4)GlcNAc beta 1-6(Gal beta 1-3)GalNacol and Fuc alpha 1-2Gal beta 1-4GlcNac beta 1-6(Gal beta 1-3)-GalNacol, in an approximate molar ratio of 3 to 4:1, respectively. Two structures are consistent with the data obtained for A3: Fuc alpha 1-2Gal beta 1-4,3(Fuc alpha 1-3,4)GlcNAc beta 1-6(Gal beta 1-3)GalNAcol and/or Gal beta 1-4,3(Fuc alpha 1-3,4)GlcNac beta 1-6(Fuc alpha 1-2Gal beta 1-3)GalNacol. The results indicate that A1 represents the "core" tetrasaccharide of the larger human cervical mucin oligosaccharides A2 and A3.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6277894

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Heterogeneity of the blood group ABH antigens and variation in the expression of these antigens of secretory granules in human cervical glands. An electron microscopic observation using lectins and monoclonal antibodies.

Authors:  Y Okamura
Journal:  Histochemistry       Date:  1990

2.  Widespread distribution in human tissues of an antigenic determinant of granulocytes.

Authors:  A J Howie; G Brown; A G Fisher; M Khan
Journal:  J Clin Pathol       Date:  1984-05       Impact factor: 3.411

3.  Further antigenic similarities of Neisseria gonorrhoeae lipooligosaccharides and human glycosphingolipids.

Authors:  R E Mandrell
Journal:  Infect Immun       Date:  1992-07       Impact factor: 3.441

4.  Expression of CD15 in tumours of the nervous system.

Authors:  G Reifenberger; P Sieth; M Niederhaus; W Wechsler
Journal:  Histochem J       Date:  1992-11

5.  Human cervicovaginal mucus contains an activity that hinders HIV-1 movement.

Authors:  S A Shukair; S A Allen; G C Cianci; D J Stieh; M R Anderson; S M Baig; C J Gioia; E J Spongberg; S M Kauffman; M D McRaven; H Y Lakougna; C Hammond; P F Kiser; T J Hope
Journal:  Mucosal Immunol       Date:  2012-09-19       Impact factor: 7.313

6.  The Effects of Hormones and Vaginal Microflora on the Glycome of the Female Genital Tract: Cervical-Vaginal Fluid.

Authors:  Bernard J Moncla; Catherine A Chappell; Brian M Debo; Leslie A Meyn
Journal:  PLoS One       Date:  2016-07-20       Impact factor: 3.240

Review 7.  Functional glycosylation in the human and mammalian uterus.

Authors:  Gary F Clark
Journal:  Fertil Res Pract       Date:  2015-10-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.